OncLive TV

Timothy N. Clinton, MD, discusses differences between genders in terms of bladder cancer presentation.

Adanma Ayanambakkam, MD, MS, discusses the safety profile of darlifarnib plus cabozantinib in ccRCC.

Jonathan Wennan Lee, MD, MSc; and Ashish Saxena, MD, PhD, discuss the future for evaluating PD-L1 expression as a biomarker in EGFR-mutated NSCLC.

Brian M. Wolpin, MD, MPH, discusses phase 1/2 data showing high activity with daraxonrasib in first-line metastatic pancreatic ductal adenocarcinoma.

Sara M. Tolaney, MD, MPH, discusses how the early-stage HER2-positive breast cancer treatment paradigm is evolving with the emergence of new phase 3 data.

Rena D. Callahan, MD, discusses the clinical utility and shifting paradigms of oral SERDs for patients with ER-positive advanced breast cancer.

Sara M. Tolaney, MD, MPH, discusses how therapeutic strategies are evolving within the HER2-positive breast cancer treatment paradigm.

Rena D. Callahan, MD, notes the implications of adding camizestrant to an aromatase inhibitor in ER-positive breast cancer with an emergent ESR1 mutation.

Jesús Berdeja, MD, discusses the optimal timing of CAR T-cell therapy referral for patients with multiple myeloma.

Adanma Ayanambakkam, MD, MS, discusses efficacy data from the phase 1a/1b FIT-001 trial.

Adanma Ayanambakkam, MD, MS, discusses the mechanism of action of darlifarnib in ccRCC.

Jonathan Wennan Lee, MD, MSc; and Ashish Saxena, MD, PhD, note data from a study of PD-L1 expression as a marker of response to TKIs in EGFR-mutated NSCLC.

Jonathan Wennan Lee, MD, MSc; and Ashish Saxena, MD, PhD, discuss the role for PD-L1 expression as a biomarker for treatment response in EGFR-mutant NSCLC.

Rena D. Callahan, MD, discusses the implications of the NATALEE trial of adjuvant ribociclib plus endocrine therapy in HR-positive early breast cancer.

Vinayak Venkataraman, MD, spotlights a focus-group study identifying mobility, autonomy, and supportive care gaps in AYA patients with sarcoma.

Taigo Kato, MD, PhD, discusses the use of ctDNA-guided therapy in patients with RCC.

Peter C. Enzinger, MD, discusses the significance of Claudin 18.2 and HER2 as actionable biomarkers in gastroesophageal cancer.

Fangdi Sun, MD, discusses how biomarker testing can help navigate the complexity of treatment decision-making across the spectrum of head and neck cancers.

Taigo Kato, MD, PhD, discusses future directions of MONSTAR-SCREEN-3 and how data from the study can be applied to clinical practice.

Taigo Kato, MD, PhD, discusses the background of the MONSTAR-SCREEN-3 in resectable RCC and the key findings from the study.

Michael Schweizer, MD, discusses the mechanism of action of mevrometostat and early-phase data with the agent in mCRPC.

Alicia Morgans, MD, MPH, discusses safety concerns and AE management with mevrometostat in mCRPC.

Lore Gruenbaum, PhD, discusses developments in mantle cell lymphoma management that she has her eye on and critical unmet needs in the field.

R. Lor Randall, MD, FACS, discusses the rationale of a meta-analysis comparing IM nailing and EP reconstruction for patients with bone metastases.

Meghan R. Flanagan, MD, MPH, discusses the multidisciplinary complexities that arise when trying to coordinate de-escalated breast cancer care.

Meghan R. Flanagan, MD, MPH, notes takeaways from a multidisciplinary tumor board discussion on how genomic assays can guide treatment decisions for DCIS.

Aaron Gerds, MD, MS, details the rationale for targeting CALR mutations in the management of myeloproliferative neoplasms

Luhua (Michael) Wang, MD, discusses the significance of the full FDA approval of brexu-cel in relapsed/refractory mantle cell lymphoma.

Dallas Gallagher, DNP, FNP-C, AOCNP, discusses the importance of a patient-focused approach when managing the emotional weight of a pancreatic cancer diagnosis.

Bradley Monk, MD, discusses the final analysis of the phase 3 KEYNOTE-B96 trial in platinum-resistant recurrent ovarian cancer.